{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:18:23Z","timestamp":1788679103719,"version":"build-2803163510"},"reference-count":30,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>There is no agreement on the optimal definitions for assessing disease state in patients with psoriatic arthritis (PsA), and some of the commonly used definitions do not include assessment of skin lesions. We investigated the performance of various definitions in patients with PsA and psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>This was a posthoc analysis of data from the PRESTA study. The remission definitions analyzed were very low disease activity (VLDA) index, defined as 7\/7 of the minimal disease activity (MDA) cutoffs; Disease Activity Index for PsA (DAPSA); and clinical (c-) DAPSA. The low disease activity (LDA) definitions analyzed were as follows: MDA defined as 5\/7 cutoffs; MDA joint with both the tender joint count (TJC) and swollen joint count (SJC) cutoffs mandated; MDA skin where skin cutoff was mandated; MDA joint + skin where TJC, SJC, and skin cutoffs were mandated; DAPSA LDA; and cDAPSA LDA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>At Week 24, the proportions of patients achieving VLDA, DAPSA, and cDAPSA remission were 10%, 35%, and 37%, respectively. Of the patients achieving DAPSA and cDAPSA remission, 55% and 56%, respectively, had Psoriasis Area and Severity Index &gt; 1. The proportions of patients achieving MDA 5\/7, MDA skin, MDA joint, and MDA joint + skin were 44%, 19%, 36%, and 14%, respectively, versus 70% achieving DAPSA and cDAPSA LDA. Notable residual levels of psoriasis were observed in patients achieving the definitions that did not require skin disease control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>VLDA and MDA definitions are more stringent than DAPSA and cDAPSA definitions for the assessment of PsA. The relevance of residual disease to patients, however, remains to be determined. [Clinical Trial registration:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"ClinicalTrials.gov\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00245960\">NCT00245960<\/jats:ext-link>]<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.180249","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T11:15:34Z","timestamp":1539602134000},"page":"160-165","source":"Crossref","is-referenced-by-count":23,"title":["Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value"],"prefix":"10.3899","volume":"46","author":[{"given":"Laura C.","family":"Coates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Boone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Szumski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"2019020109251877000_46.2.160.1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrrheum.2011.125","article-title":"Management of psoriatic arthritis from the view of the dermatologist","volume":"7","author":"Chang","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2019020109251877000_46.2.160.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.022"},{"key":"2019020109251877000_46.2.160.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"2019020109251877000_46.2.160.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"2019020109251877000_46.2.160.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.09.003"},{"key":"2019020109251877000_46.2.160.6","doi-asserted-by":"publisher","DOI":"10.1080\/09546630600823369"},{"key":"2019020109251877000_46.2.160.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.008"},{"key":"2019020109251877000_46.2.160.8","doi-asserted-by":"publisher","DOI":"10.1080\/000155500300012873"},{"key":"2019020109251877000_46.2.160.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200350"},{"key":"2019020109251877000_46.2.160.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"2019020109251877000_46.2.160.11","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/14656566.2017.1378343","article-title":"Small molecule therapy for managing moderate to severe psoriatic arthritis","volume":"18","author":"Costa","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"2019020109251877000_46.2.160.12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0000000000000583","article-title":"A systematic review and meta-analysis of efficacy and safety of novel interleukin inhibitors in the management of psoriatic arthritis","volume":"24","author":"Bilal","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2019020109251877000_46.2.160.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"2019020109251877000_46.2.160.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120970"},{"key":"2019020109251877000_46.2.160.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150805"},{"key":"2019020109251877000_46.2.160.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170112"},{"key":"2019020109251877000_46.2.160.17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/1744666X.2014.878649","article-title":"Ustekinumab for the treatment of psoriatic arthritis","volume":"10","author":"Wofford","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"2019020109251877000_46.2.160.18","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"2019020109251877000_46.2.160.19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"2019020109251877000_46.2.160.20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-14-101"},{"key":"2019020109251877000_46.2.160.21","unstructured":"Lubrano E Mesina F Caporali R . Clinical remission in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2018 Mar 16 (E-pub ahead of print)."},{"key":"2019020109251877000_46.2.160.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2019020109251877000_46.2.160.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150826"},{"key":"2019020109251877000_46.2.160.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2019020109251877000_46.2.160.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c147"},{"key":"2019020109251877000_46.2.160.26","unstructured":"WINPEPI (PEPI-for-Windows) . [Internet. Accessed August 22, 2018.] Available from: www.brixtonhealth.com\/pepi4windows.html"},{"key":"2019020109251877000_46.2.160.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08628.x"},{"key":"2019020109251877000_46.2.160.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211998"},{"key":"2019020109251877000_46.2.160.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170449"},{"key":"2019020109251877000_46.2.160.30","doi-asserted-by":"crossref","unstructured":"Wervers K Vis M Tchetverikov I Gerards AH Kok MR Appels CWY Burden of psoriatic arthritis in different definitions of disease activity: comparing Minimal Disease Activity and Disease Activity index for Psoriatic Arthritis. Arthritis Care Res 2018 Apr 2 (E-pub ahead of print).","DOI":"10.1136\/annrheumdis-2018-eular.4578"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.180249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T18:08:31Z","timestamp":1572113311000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.180249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,1]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.3899\/jrheum.180249"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.180249","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]}}}